In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lucie Ellis-Taitt

Managing Editor, In Vivo

London, UK
Prior to leading In Vivo, Lucie was a senior editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo online as well as the annual Outlook publication. Covering the biopharma space since 2012, Lucie writes feature articles on the topics of leadership, R&D, innovation and more. She also regularly attends industry events and moderates panel discussions on topics such as investment trends, women’s health and R&D hot topics.

Latest From Lucie Ellis-Taitt

Formation Secures Huge Series D For AI Platform Growth

Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi. 

Artificial Intelligence Deals

Podcast: Navigating Challenges – The Changing Role Of Big Pharma

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

Market Access C-Suite Speaks

‘Potentially Groundbreaking’ – Grey Wolf Advances IO Technology

Grey Wolf Therapeutics has secured $99m via an expanded series B financing to advance its antigen modulation approach in cancer and to further explore its use in autoimmune disease indications.

Clinical Trials Financing

Regeneron Aiming To Be A Cell And Gene Medicine ‘Powerhouse’

Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline. 

Regenerative Medicine Innovation

VC Insights On Future Tech And Future Leaders

“I'm a strong believer in creating the right mix between young ambitious people and pairing them up with someone experienced,” says Jeroen Bakker, who is focused on biotech company creation at Seed Investments, Novo Holdings.  

Leadership Financing

Podcast: ‘Pharma Is Not Just A Cost Component’ – Showcasing Value As Well As Innovation

Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.

Market Access C-Suite Speaks
See All